MPN-RC Monthly Publication

Title: Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms

Authors: Jeremy Wen, Anitria Cotton, Rashid Mehmood, Man Mohan, Trent Hall, Amber L. Broadhurst, Kevin Zhang, Yunusa Olufadi, Guoian Kang, Bridget Marcellino, John Mascarenhas, Ronald Hoffman, Laura J. Janke, Sandeep Gurbuxani, Gerard M. McGeehan, John Crispino

Full Article

Consortium Member of the Month

Our consortium members of the month for the month of August goes to Dr. Jeremy Wen and Anitria Cotton from St. Jude Children’s Research Hospital!

Dr. Jeremy Wen (Left) and Anitria Cotton (Right)

Dr. Wen - Lead Scientist

Anitria Cotton - Lab Operations Manager

Dr. Jeremy Wen and Anitria Cotton are members of Dr. John Crispino’s laboratory at St. Jude Children’s Research Hospital in Memphis, Tennessee. They are outstanding scientists dedicated to developing novel therapies for patients with myeloproliferative neoplasms. Most recently, they led an investigation into the role of menin—an interaction partner of KMT2A and an established therapeutic target in acute leukemia—in the aberrant megakaryopoiesis that characterizes myelofibrosis. Their work demonstrated that menin inhibition represents a promising therapeutic strategy for MPNs, and they are enthusiastic about collaborating with the consortium on correlative studies associated with an upcoming MPN-RC clinical trial.

Nominated by: Dr. John Crispino

Dr. Wen and Anitria, thank you both so much for all of the phenomenal work you have done for the consortium.

Keep up the great work!

ASH Conference 2025

(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!
(Left to Right: Md. Babu Mia, Noushin Rahnamay, Dr. Bridget Marcellino, and Dr. Raajit Rampal) The Mount Sinai and Memorial Sloan Kettering group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.

ASH Abstracts

Marina Kremyanskaya, MD,PhD

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Full ASH Abstract
John Crispino, PhD,MBA

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Full Ash Abstract
John Mascarenhas, MD

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Full ASH Abstract
Andrew Kuykendall, MD

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Full Ash Abstract
Min Lu, MD,PhD

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Full ASH Abstract
Xiaoli Wang, MD,PhD

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Full Ash Abstract
MD Babu Mia, PhD

Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

Full ASH Abstract